FDA expected to decide on AstraZeneca's self-administered flu vaccine next quarter
If all goes well at the FDA, AstraZeneca hopes to roll out the US’ first self-administered flu vaccine ahead of the next cold and flu season, the company announced on Tuesday.
AstraZeneca’s FluMist Quadrivalent nasal spray was approved roughly two decades ago for administration by a healthcare professional. But if regulators OK AstraZeneca’s latest application, eligible people would be able to receive the vaccine by mail and administer it themselves or to someone in their care.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.